|  |
| --- |
| Supplementary Table 1 Clinical characteristics of breast cancer patients |
| Characteristics | Numbers of cases (%) |
| Age |  |
| NA | 2(0.18) |
| <60>=60 | 589(53.35)513(46.47) |
| Gender |  |
| NA | 2(0.18) |
| Female | 1090(98.73) |
| Male | 12(1.09) |
| Histological type |  |
| NA | 3(0.27) |
| Infiltrating Ductal Carcinoma | 790(71.56) |
| Infiltrating Lobular Carcinoma | 204(18.48) |
| Other | 107(9.69) |
| Molecular subtype |  |
| NA | 255(23.1) |
| Basal | 142(12.86) |
| Her2 | 67(6.07) |
| LumA | 422(38.22) |
| LumB | 194(17.57) |
| Normal | 24(2.17) |
| ER |  |
| NA | 50(4.53) |
| Indeterminate | 2(0.18) |
| Negative | 239(21.65) |
| Positive | 813(73.64) |
| PR |  |
| NA | 51(4.62) |
| Indeterminate | 4(0.36) |
| Negative | 345(31.25) |
| Positive | 704(63.77) |
| HER2 |  |
| NA | 183(16.58) |
| Equivocal | 180(16.3) |
| Indeterminate | 12(1.09) |
| Negative | 565(51.18) |
| Positive | 164(14.86) |
| Menopause status |  |
| NA | 93(8.42) |
| Inde | 34(3.08) |
| Peri | 40(3.62) |
| Post | 706(63.95) |
| Pre  | 231(20.92) |
| T classification |  |
| NA | 2(0.18) |
| T1 | 281(25.45) |
| T2 | 640(57.97) |
| T3 | 138(12.5) |
| T4 | 40(3.62) |
| TX | 3(0.27) |
| N classification |  |
| NA | 2(0.18) |
| N0 | 516(46.74) |
| N1 | 367(33.24) |
| N2 | 120(10.87) |
| N3 | 79(7.16) |
| NX | 20(1.81) |
| M classification |  |
| NA | 2(0.18) |
| M0 | 917(83.06) |
| M1 | 22(1.99) |
| MX | 163(14.76) |
| Stage |  |
| NA | 10(0.91) |
| I | 182(16.49) |
| II | 626(56.7) |
| III | 252(22.83) |
| IV | 20(1.81) |
| X | 14(1.27) |
| Lymph node status |  |
| NA | 379(34.33) |
| No | 28(2.54) |
| Yes | 697(63.13) |
| Margin status |  |
| NA | 72(6.52) |
| Close | 31(2.81) |
| Negative | 922(83.51) |
| Positive | 79(7.16) |
| Vital status |  |
| NA | 2(0.18) |
| Deceased | 155(14.04) |
| Living | 947(85.78) |
| Radiation therapy |  |
| NA | 102(9.24) |
| No | 445(40.31) |
| Yes | 557(50.45) |
| Neoadjuvant treatment |  |
| NA | 3(0.27) |
| No | 1088(98.55) |
| Yes | 13(1.18) |
| Targeted molecular therapy |  |
| NA | 525(47.55) |
| No | 46(4.17) |
| Yes | 533(48.28) |
| Sample type |  |
| Metastatic | 7(0.63) |
| Primary Tumor | 1097(99.37) |
| OS |  |
| 0 | 933(85.83) |
| 1 | 154(14.17) |
| RFS |  |
| 0 | 816(89.47) |
| 1 | 96(10.53) |
| KLRB1 |  |
| High | 723(65.49) |
| Low | 381(34.51) |

Abbreviation: NA, not available.